Significantly greater composite adverse outcome rates seen for long- versus short-term inhaled corticosteroid use for prevalent, inception cohorts.

You have full access to this article via your institution. Available treatments for COPD are mainly palliative, and there are no therapies available that halt the decline in lung function or the ...

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

Whether finding new treatments for schizophrenia or first-time ways to tackle bladder cancer, these companies are finding ...

Following recent approvals in the EU, China and the U.S., this approval was based on pivotal Phase 3 results in adults with elevated eosinophils ...

Japan’s Ministry of Health, Labor and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent ...

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

About half of COPD patients continue to experience exacerbations despite being on triple inhaled therapy. Patients with COPD and elevated eosinophils have an increased risk of exacerbations and ...

China: A recent multicenter randomized controlled trial has highlighted the potential benefits of acupuncture as a ...

The Ministry of Health, Labour and Welfare in Japan has granted marketing and manufacturing authorization for Dupixent (dupilumab) for the treatment of chronic obstructive pulmonary disease (COPD) in ...